Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study

Conclusions-the 20/20/20 risk stratification model adequately predicted progression in our population and is easy to use in various clinical settings.PMID:34073289 | PMC:PMC8161809 | DOI:10.3390/curroncol28030188

Source: Current Oncology - June 2, 2021 Category: Cancer & Oncology Authors: Camille Tessier Thomas Allard Jean-Samuel Boudreault Rayan Kaedbey Vincent Éthier Fl échère Fortin Michel Pavic Source Type: research